Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL), noting that the company's lead drug candidate, IHL-42X, has transitioned from regulatory preparation into active clinical execution. According to the update, first-patient dosing is now underway in the DReAMzz study, a Phase 2/3 trial evaluating the treatment in patients with obstructive sleep apnea.
The DReAMzz study is enrolling approximately 120 patients across nine dose combinations and 14 U.S. sites, with completion expected in mid-2027. Importantly, the study is designed to refine the dose ratio ahead of a planned Phase 3 program, rather than replicate the efficacy work already conducted in the RePOSA trial. This sequencing should improve confidence in dose selection and Phase 3 trial design before Incannex commits to the higher development spending associated with late-stage studies.
From a financial perspective, Incannex reported $68.4 million in unrestricted cash as of September 24. Management states this provides runway for at least 12 months of planned operations. However, the company's 10-K filing explicitly notes that substantial additional funding will be required beyond that period. While the balance sheet reduces near-term financing pressure, it does not eliminate longer-term capital needs.
The pipeline has also become more concentrated. PSX-001 remains the principal secondary clinical asset, while the Australian Phase 2 study of IHL-675A in rheumatoid arthritis was terminated due to recruitment challenges and produced insufficient data to assess efficacy or safety. As a result, the equity story is increasingly centered on IHL-42X and the eventual transition from DReAMzz to Phase 3.
For investors, the next several quarters should be measured primarily by enrollment cadence, dose optimization, and whether the DReAMzz study supports a more clearly defined Phase 3 design, rather than near-term profit and loss trends. Stonegate's update underscores that the company's near-term value proposition hinges on clinical execution rather than immediate financial performance.
To view the full announcement, including downloadable images, bios, and more, click here. The announcement is distributed by Reportable, Inc.
